These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 15555594

  • 1. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY.
    Biochem Biophys Res Commun; 2004 Dec 24; 325(4):1472-80. PubMed ID: 15555594
    [Abstract] [Full Text] [Related]

  • 2. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.
    J Bone Miner Res; 2003 Dec 24; 18(12):2159-68. PubMed ID: 14672351
    [Abstract] [Full Text] [Related]

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun 24; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 4. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T.
    J Cell Physiol; 2001 Aug 24; 188(2):236-42. PubMed ID: 11424090
    [Abstract] [Full Text] [Related]

  • 5. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.
    Bone; 2006 May 24; 38(5):678-85. PubMed ID: 16309985
    [Abstract] [Full Text] [Related]

  • 6. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL.
    Kawaida R, Ohtsuka T, Okutsu J, Takahashi T, Kadono Y, Oda H, Hikita A, Nakamura K, Tanaka S, Furukawa H.
    J Exp Med; 2003 Apr 21; 197(8):1029-35. PubMed ID: 12707301
    [Abstract] [Full Text] [Related]

  • 7. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK.
    Biochem Biophys Res Commun; 2009 Jan 16; 378(3):645-9. PubMed ID: 19059209
    [Abstract] [Full Text] [Related]

  • 8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 16; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 9. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.
    Biochem Biophys Res Commun; 2005 Mar 04; 328(1):91-7. PubMed ID: 15670755
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF.
    Biochem Pharmacol; 2005 Jul 15; 70(2):300-7. PubMed ID: 15919055
    [Abstract] [Full Text] [Related]

  • 11. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T.
    J Periodontal Res; 2006 Aug 17; 41(4):273-9. PubMed ID: 16827720
    [Abstract] [Full Text] [Related]

  • 13. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
    Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, Brazier M.
    J Cell Biochem; 2004 May 15; 92(2):285-95. PubMed ID: 15108355
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
    Kwak HB, Lee SW, Li YJ, Kim YA, Han SY, Jhon GJ, Kim HH, Lee ZH.
    Biochem Pharmacol; 2004 Apr 01; 67(7):1239-48. PubMed ID: 15013839
    [Abstract] [Full Text] [Related]

  • 15. Serotonin regulates osteoclast differentiation through its transporter.
    Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P.
    J Bone Miner Res; 2004 Sep 01; 19(9):1420-31. PubMed ID: 15312242
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):839-45. PubMed ID: 15752732
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.
    Kim MH, Ryu SY, Bae MA, Choi JS, Min YK, Kim SH.
    Food Chem Toxicol; 2008 Nov 15; 46(11):3375-82. PubMed ID: 18786594
    [Abstract] [Full Text] [Related]

  • 19. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb 15; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.